Purdue’s Point of No Return
Purdue’s decision to pull OxyContin sales reps highlights what has been the biggest part of marketing budgets. Did we just see the tipping point?
Sales
Five things for pharma marketers to know: Monday, January 22, 2018
Sanofi to buy Bioverativ for $11.6 billion; Celgene to acquire Juno for $9 billion; Teva to lay off more than 200 in Philadelphia
Five things for pharma marketers to know: Wednesday, January 17, 2018
Celgene reportedly in talks to buy Juno; Novartis’ Kymriah receives fast-track reviews in U.S. and Europe; BI’s Gilotrif gets expanded approval in lung cancer
Five things for pharma marketers to know: Tuesday, December 26, 2017
Roche to buy Ignyta for $1.7 billion; FDA OKs Valeant eye drop for OTC sale; Kmart settles prescription drug fraud allegations
Five things for pharma marketers to know: Wednesday, December 20, 2017
Tax bill could lead pharma to move overseas; global pharma sales increased 45% in nine years; FDA OKs first gene therapy for rare retinal disease
Five things for pharma marketers to know: Thursday, December 14, 2017
Pharma R&D return on investment falls to eight-year low; FDA approves Pfizer’s biosimilar to J&J’s Remicade; Novartis to downsize generics business
Five things for pharma marketers to know: Wednesday, December 13, 2017
Teva diminishes debt with job cuts and sale; FDA to study whether consumers can detect misleading ads; AbbVie, Roche present positive Phase-III data at ASH
Five things for pharma marketers to know: Wednesday, November 29, 2017
U.K. to be first to sell OTC Viagra; Regeneron offers startup scientific expertise; docs more likely to get poor marks when they reject patient requests
Five things for pharma marketers to know: Monday, November 13, 2017
Dynavax receives FDA approval for hepatitis-B vaccine; Novartis strikes R&D deal with gene-editing startup; White House nominates new HHS head
Five things for pharma marketers to know: Thursday, November 9, 2017
GSK hires Google biotech exec to lead R&D; Merck gets FDA-approval for CMV therapy; ex-Lilly exec reportedly top HHS secretary pick
